Kimball Electronics acquires Helvoet for €90M (~$103M); establishes global medical CDMO platform

Kimball Electronics, Inc.

Purchase price €90M (~$103M); funded with cash and existing credit lines; closed July 1, 2026.
Helvoet is a medical CDMO specializing in micro-molding, microfluidics, diagnostics, drug delivery; 2025 revenue ~$56M, EBITDA margin mid-teens.
Transaction valued at ~9x estimated 2026 adjusted EBITDA; expected to be accretive to fiscal 2027 adjusted earnings.
Helvoet CEO Eveline Hogenkamp to remain; operations in Netherlands and India; complements Kimball's Indianapolis facility.
Acquisition establishes global medical CMO platform; expands European and India footprint; blue-chip customer base.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.